A

Assertio Holdings Inc
NASDAQ:ASRT

Watchlist Manager
Assertio Holdings Inc
NASDAQ:ASRT
Watchlist
Price: 0.98 USD 0.1%
Market Cap: 93.4m USD
Have any thoughts about
Assertio Holdings Inc?
Write Note

Assertio Holdings Inc
Other Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Assertio Holdings Inc
Other Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
A
Assertio Holdings Inc
NASDAQ:ASRT
Other Current Liabilities
$3m
CAGR 3-Years
-43%
CAGR 5-Years
N/A
CAGR 10-Years
-27%
Johnson & Johnson
NYSE:JNJ
Other Current Liabilities
$4.8B
CAGR 3-Years
31%
CAGR 5-Years
10%
CAGR 10-Years
12%
Bristol-Myers Squibb Co
NYSE:BMY
Other Current Liabilities
$4.8B
CAGR 3-Years
9%
CAGR 5-Years
24%
CAGR 10-Years
9%
Pfizer Inc
NYSE:PFE
Other Current Liabilities
$24.2B
CAGR 3-Years
-8%
CAGR 5-Years
12%
CAGR 10-Years
10%
Merck & Co Inc
NYSE:MRK
Other Current Liabilities
$7.2B
CAGR 3-Years
40%
CAGR 5-Years
24%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Other Current Liabilities
$5.6B
CAGR 3-Years
30%
CAGR 5-Years
21%
CAGR 10-Years
5%
No Stocks Found

Assertio Holdings Inc
Glance View

Market Cap
93.5m USD
Industry
Pharmaceuticals

Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. The company is headquartered in Lake Forest, Illinois and currently employs 19 full-time employees. The firm's primary marketed products are INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, INDOCIN (indomethacin) Oral Suspension, CAMBIA (diclofenac potassium for oral solution), Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray and Zipsor (diclofenac potassium) Liquid filled capsules. The firm has other commercially available products, which include OXAYDO (oxycodone HCI, USP) tablets for oral use only. Assertio and Zyla are the registered trademarks of the Company. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.

ASRT Intrinsic Value
1.56 USD
Undervaluation 37%
Intrinsic Value
Price
A

See Also

What is Assertio Holdings Inc's Other Current Liabilities?
Other Current Liabilities
3m USD

Based on the financial report for Sep 30, 2024, Assertio Holdings Inc's Other Current Liabilities amounts to 3m USD.

What is Assertio Holdings Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
-27%

Over the last year, the Other Current Liabilities growth was -79%. The average annual Other Current Liabilities growth rates for Assertio Holdings Inc have been -43% over the past three years , and -27% over the past ten years .

Back to Top